Is Cord Tissue Banking Worth It?
New Cord Tissue Research, Aggressive Product Development and Lower Prices Make Cord Tissue
Banking More Appealing
NEW YORK, Feb. 3, 2014 - When Americord validated its proprietary method for harvesting and
preserving...
More
Is Cord Tissue Banking Worth It?
New Cord Tissue Research, Aggressive Product Development and Lower Prices Make Cord Tissue
Banking More Appealing
NEW YORK, Feb. 3, 2014 - When Americord validated its proprietary method for harvesting and
preserving mesenchymal stem cells (MSCs) from placenta tissue late last year, it joined leaders in the
global scientific community who are increasingly investing significant resources in what many researchers
believe represents the future of stem cell-based medical therapies. Found in vast quantities in both cord
and placenta tissue, MSCs have unique properties that scientists believe may make them invaluable in the
treatment of numerous diseases and regenerative therapies.
Management believes Americord is the first cord blood banking company to harvest and store MSCs from
both cord tissue and placenta tissue in the United States, and is the first to bring to market a way to collect
and store MSCs from placenta tissue. MSCs are widely considered to be
Less